Evrópusambandið - íslenska - EMA (European Medicines Agency)

takeda manufacturing austria ag - manna prótein c - purpura fulminans; protein c deficiency - blóðþurrðandi lyf - ceprotin is indicated for prophylaxis and treatment of  purpura fulminans  coumarin-induced skin necrosis and venous thrombotic events in patients with severe congenital protein c deficiency.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

pfizer europe ma eeig  - pegfilgrastim - daufkyrningafæð - Ónæmisörvandi, - lækkun á lengd mæði í tengslum og tíðni hita og mæði í tengslum í fullorðinn sjúklinga með frumudrepandi lyfjameðferð fyrir illkynja (með undantekning langvarandi merg hvítblæði og myelodysplastic heilkennum).

Evrópusambandið - íslenska - EMA (European Medicines Agency)

viatris limited - tadalafil - háþrýstingur, lungnabólga - Þvaglát - talmanco er ætlað í fullorðnir fyrir meðferð lungum slagæð háan blóðþrýsting (pah) flokkast sem hagnýtur ii og iii, til að bæta æfing getu. verkun hefur verið sýnd í sjálfvakta pah (ipah) og í pah í tengslum við krabbameinsvaldandi sjúkdóma.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - Æxlishemjandi lyf - vegzelma in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. vegzelma in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. sjá nánar í kafla 5 til að fá nánari upplýsingar varðandi húðþéttni vaxtarþáttar viðtaka 2 (her2). vegzelma in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with vegzelma in combination with capecitabine. nánari upplýsingar um her2 stöðu, sjá kafla 5. vegzelma, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer (nsclc) other than predominantly squamous cell histology. vegzelma, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent nsclc with epidermal growth factor receptor (egfr) activating mutations (see section 5. vegzelma, in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. vegzelma, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. vegzelma, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (vegf) inhibitors or vegf receptor–targeted agents. vegzelma in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. vegzelma, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

omrix biopharmaceuticals n. v. - mannafíbrógen manna, trombín manna - hemostasis, skurðaðgerð - antihemorrhagics - evicel er notað sem stuðningsmeðferð í skurðaðgerð þar sem staðlað skurðaðgerð er ófullnægjandi til að bæta blóðflæði. evicel er einnig ætlað eins og suture stuðning fyrir blóðstorknun í æðum skurðaðgerð.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

novo nordisk a/s - nonacog beta pegol - hemophilia b - antihemorrhagics - meðferð og fyrirbyggja blæðingar í sjúklinga með dreyrasýki b (meðfædda þáttur laga skort). , refixia can be used for all age groups.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

linde sverige ab - dinitrogenii oxidum; oxygenium - lyfjagas undir þrýstingi - 50/50 %

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

baxter medical ab* - cyclophosphamidum inn - tafla - 50 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

baxter medical ab* - cyclophosphamidum inn - stungulyfsstofn, lausn - 1 g

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

baxter medical ab* - cyclophosphamidum inn - stungulyfsstofn, lausn - 500 mg